This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
(November 2012) (Learn how and when to remove this template message)
|Chemical and physical data|
|Molar mass||144233.81 g·mol−1|
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2. It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix. Its development has been discontinued.
- "Dusigitumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- Osher E, Macaulay VM (August 2019). "Therapeutic Targeting of the IGF Axis". Cells. 8 (8): 895. doi:10.3390/cells8080895. PMC 6721736. PMID 31416218.
- "Dusigitumab - MedImmune". AdisInsight. Springer Nature Switzerland AG.